Key facts
- This page summarizes Larry Robbins's Form 4 filing for CVS HEALTH Corp (CVS).
- 1 reported transaction and 2 derivative rows are listed below.
- Accepted by SEC: 25 Nov 2024, 18:10.
Larry Robbins - 21 Nov 2024 Form 4 Insider Report for CVS HEALTH Corp (CVS)
- Reporting relationship
- Director
- Issuer ticker
- CVS
- Reported as of
- 21 Nov 2024
- Net transaction value
- +$167,500
- SEC form
- 4
- Accepted by SEC
- 25 Nov 2024, 18:10:19 UTC
- Prior SEC filing
- 25 Nov 2024
- Next SEC filing
- 06 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Larry Robbins
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Larry Robbins filed Form 4 for CVS HEALTH Corp (CVS) on 25 Nov 2024.
Change
- Previous filing in this sequence was filed on 25 Nov 2024.
- Current net transaction value: +$167,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CVS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,946,799
- Date
- 21 Nov 2024
- Ownership
- Held by Glenview Investment Funds
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CVS
transaction
Derivative
Deferred Stock Units
Award
- Transaction value
- $167,500
- Shares
- +2,933
- Change %
- Price
- $57.10
- Shares after
- 2,933
- Date
- 21 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,933
- Exercise price
- $0.000000
- Footnotes
- F6, F7
CVS
holding
Derivative
Cash-Settled Swaps
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 378,000
- Date
- 21 Nov 2024
- Ownership
- Held by Glenview InvestmentFunds
- Underlying class
- Common Stock
- Underlying amount
- 378,000
- Exercise price
- $0.000000
- Footnotes
- F2, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
These shares of the Issuer's common stock (the "Shares") are held for the accounts of Glenview Capital Master Fund, Ltd., Glenview Offshore Opportunity Master Fund, Ltd. (the "GO Fund"), Glenview Healthcare Master Fund, L.P., and GCM Suggestivist I Master Fund, L.P. (the "Glenview Investment Funds").
Footnote F2
The Reporting Person disclaims beneficial ownership over any securities owned by the Glenview Investment Funds other than to the extent of any pecuniary interest he may have therein.
Footnote F3
The Glenview Investment Funds are the record holders of the Shares. The Reporting Person is the Founder, Portfolio Manager and CEO of Glenview Capital Management, LLC, which serves as investment manager to each of the Glenview Investment Funds. The Reporting Person shares voting and dispositive power over the Shares held by the Glenview Investment Funds and may be deemed to beneficially own such Shares.
Footnote F4
These cash-settled swaps reference shares of the Issuer's common stock (the "Swaps") and are held for the account of the GO Fund.
Footnote F5
The GO Fund is the record holder of the Swaps. The Reporting Person is the Founder, Portfolio Manager and CEO of Glenview Capital Management, LLC, which serves as investment manager to the GO Fund. The Reporting Person shares voting and dispositive power over the Swaps held by the GO Fund and may be deemed to beneficially own such Swaps.
Footnote F6
Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the 2017 Incentive Compensation Plan.
Footnote F7
Consists of deferred stock units, each to be converted into one share of common stock and issued upon the Reporting Person's retirement from the Issuer's Board of Directors, as elected by the Reporting Person.